Article

TRUST/Ocular TRUST data document durability of fluoroquinolone activity nationwide

TRUST and Ocular TRUST are nationwide surveillance programs monitoring antimicrobial susceptibility of specific pathogens to a broad array of antibiotics, including fluoroquinolones.

To get a better understanding of antimicrobial susceptibility patterns over time, the microbiology and internal medicine communities rely on the TRUST (Tracking Resistance in the United States Today) study, an ongoing surveillance program that has collected more than 70,000 isolates from a network of more than 200 laboratories throughout the country over the last 10 years, said Penny A. Asbell, MD, FACS, MBA, professor of ophthalmology and director of the cornea and refractive surgery service at Mount Sinai School of Medicine in New York.

This annual surveillance program began in 1996 when the fluoroquinolone levofloxacin (Levaquin, Ortho-McNeil) was introduced as a systemic agent to treat respiratory infections such as pneumonia, Dr. Asbell said. Levofloxacin ophthalmic solution 0.5% (Quixin, Vistakon Pharmaceuticals) was introduced 4 years later. Because resistance to penicillin and other systemic antibiotics had developed with widespread use, TRUST was launched to monitor for trends of emerging fluoroquinolone resistance. The TRUST program collects isolates from laboratories throughout the country and performs all testing at a single, centralized laboratory using standardized methodology.

According to Dr. Asbell, data from the ocular isolates collected in TRUST matched the overall surveillance results. Susceptibility of ocular S pneumoniae and Haemophilus influenzae to levofloxacin continues to be more than 99% and identical to the two other newer ophthalmic fluoroquinolones, gatifloxacin 0.3% (Zymar, Allergan) and moxifloxacin 0.5% (Vigamox, Alcon Laboratories). S pneumoniae susceptibility to ciprofloxacin (Ciloxan, Alcon), an older fluoroquinolone also used topically, has decreased slightly over time, however, Dr. Asbell said.

"Out of more than 1,000 ocular isolates collected between 1999 and 2006, all but one S pneumoniae and one H influenzae isolate were susceptible to levofloxacin, gatifloxacin, and moxifloxacin. That's a remarkable indication that resistance to these fluoroquinolones has not developed in these ocular pathogens," she said.

Because these newer fluoroquinolone antibiotics all work similarly, one should expect similar results, she added. But although the TRUST dataset is a valuable and publicly available source of information that may help in making antibiotic treatment decisions, Dr. Asbell cautioned that laboratory data do not necessarily reflect clinical response.

To serve the ophthalmology community better, a new initiative modeled after the TRUST study has been launched. Ocular TRUST specifically collects ocular isolates from eye centers and community hospitals across the United States and determines susceptibilities to a panel of nine antimicrobials. The first Ocular TRUST study included Staphylococcus aureus as well as S pneumoniae and H influenzae. For future studies, the pathogen panel has been expanded to include coagulase-negative staphylococci and Pseudomonas aeruginosa.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.